Loading

Foamix Pharmaceuticals

Menlo has combined with Foamix Pharmaceuticals creating a leading biopharma company focused on the commercialization and development of therapeutics to serve patients in the dermatology space.
null

Leadership

Our leadership team brings together significant clinical development, regulatory, manufacturing and commercialization experience to advance serlopitant for the treatment of several conditions with significant unmet medical need.
null

Board of Directors

Our experienced board of directors consists of David Domzalski, Steve Basta, Sharon Barbari, Rex Bright, Tony Bruno, Dr. Stanley Hirsch, and Elisabeth Sandoval.

Pipeline of Indications

Diversified Dermatology-Focused Pipeline with Near Term Milestones
Safety and efficacy of these investigational products have not been established.
There is no guarantee that pipeline products will receive FDA approval or become commercially available.

Diversified Dermatology-Focused Pipeline with Near Term Milestones
Safety and efficacy of these investigational products have not been established. There is no guarantee that pipeline products will receive FDA approval or become commercially available.
Newsroom